Browsing by Subject "fibrosing alveolitis"
Now showing items 1-18 of 18
-
Applied proteomics in companion animal medicine
(2016)Background: Proteomics in companion animal medicine has been used chiefly, in order to identify proteins, which may be used as biomarkers for early diagnosis of a variety of pathological conditions, as well as to elucidate ... -
Calprotectin in lung diseases
(2021)Calprotectin (CLP) is a heterodimer formed by two S‐100 calcium‐binding cytosolic pro-teins, S100A8 and S100A9. It is a multifunctional protein expressed mainly by neutrophils and released extracellularly by activated or ... -
CD8+T lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis
(2007)Background. Recently it was shown that in Idiopathic Pulmonary Fibrosis (IPF) tissue infiltrating CD8+ T lymphocytes (TLs) are associated with breathlessness and physiological indices of disease severity, as well as that ... -
Clinical relevance of circulating autoantibodies in idiopathic pulmonary fibrosis; A NAt hard to break
(2022)Patients with idiopathic pulmonary fibrosis are screened for circulating autoantibodies as part of the initial interstitial lung disease workup. Management of seropositive idiopathic pulmonary fibrosis is currently considered ... -
Design, Rationale, Methodology, and Aims of a Greek Prospective Idiopathic Pulmonary Fibrosis Registry: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF)
(2018)Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown origin. Despite the fact that the guidelines on the diagnosis and management of the disease were updated in 2015, ... -
Detection of mitochondrial transfer RNA (mt-tRNA) gene mutations in patients with idiopathic pulmonary fibrosis and sarcoidosis
(2018)Mitochondrial reactive oxygen species production may lead to tissue injury associated with two respiratory disorders of unknown origin which are shared by common tissue fibrosis, IPF and sarcoidosis. Sequence analysis of ... -
Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial “impact” beyond any expectation
(2021)[No abstract available] -
Efficacy and safety of nintedanib in a greek multicentre idiopathic pulmonary fibrosis registry: A retrospective, observational, cohort study
(2020)Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF). In a retrospective, real-world study across seven Greek hospitals, we evaluated the effectiveness and safety of ... -
Genotype-Phenotype Relationships in Inheritable Idiopathic Pulmonary Fibrosis: A Greek National Cohort Study
(2022)Background: Monogenic and polygenic inheritances are evidenced for idiopathic pulmonary fibrosis (IPF). Pathogenic variations in surfactant protein-related genes, telomere-related genes (TRGs), and a single-nucleotide ... -
ICAM-1, ICAM-2 and ICAM-3 in the sera of patients with idiopathic pulmonary fibrosis
(2004)In order to test the serum levels of ICAM-1, ICAM-2 and ICAM-3 in patients with idiopathic pulmonary fibrosis (IPF), twenty patients with IPF and eleven with secondary interstitial fibrosis (SIF), as well as forty healthy ... -
Idiopathic pulmonary fibrosis patients’ COVID-19 quarantine; not just a routine
(2020)[No abstract available] -
Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis
(2021)Background: Idiopathic Pulmonary Fibrosis (IPF) represents a chronic lung disease with unpredictable course. Methods: We aimed to investigate prognostic performance of complete blood count parameters in IPF. Treatment-naïve ... -
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece
(2020)Background: Abundant evidence supports an association between Idiopathic Pulmonary Fibrosis (IPF) and lung cancer development. Data on diagnosis and management of patients with IPF and lung cancer are still scarce. Patients ... -
The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis
(2008)Background: The Medical Research Council (MRC) chronic dyspnea scale (6-point) is used in different clinical conditions to grade breathlessness on daily activities. We have previously shown that in patients with histologically ... -
Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
(2022)[No abstract available] -
Utilizing a Homecare Platform for Remote Monitoring of Patients with Idiopathic Pulmonary Fibrosis
(2017)Homecare and home telemonitoring are a focal point of emerging healthcare schemes, with proven benefits for both patients, caregivers and providers, including reduction of healthcare costs and improved patients’ quality ...